Advocacy & Knowledge
Rising Sun 2011: CML Patient advocates from Asian countries convened in Singapore
On 18-20 March 2011, patient representatives from 16 countries met in Singapore for the conference "Rising Sun 2011", the second annual meeting for CML advocates from the Asia-Pacific region. This event was truly a "dream come true" for Asian CML advocates, giving them an opportunity to meet peers, develop tight connections and learn from each other. With this year's representatives from China, Hong Kong, Korea, India, Indonesia, Malaysia, Philippines, Singapore, Taiwan, Thailand and Vietnam, Rising Sun had become a key meeting for CML patient groups. Speakers from these countries were joined by speakers from Australia, New Zealand, Germany, Switzerland and the USA.
World Cancer Day 2011, Maximized: The Max Foundation submits 13.000 signatures to World Cancer Declaration
A delegation representing the Max Foundation's Maximize Life Movement arrived in Geneva on World Cancer Day (4 Feb 2011) and delivered 13,000 signatures endorsing the World Cancer Declaration to the Union for International Cancer Control (UICC). On behalf of 30 patient associations as well as volunteers and committed individuals in 87 countries, the five delegates brought with them the spirit and energy of everyone who embraces the Maximize Life Movement. Read more here
CML Advocates Network and iCMLf join forces on Paediatric CML on International Childhood Cancer Day
The "CML Advocates Network", the international platform of patient groups supporting patients and relatives suffering from Chronic Myeloid Leukaemia, and the International CML Foundation join forces to support young patients affected by that rare form of leukaemia, as well as physicians and researchers. The project, launched on International Childhood Cancer Day on 15 February 2011, will encompass a range of activities to support collaboration and sharing of experience of parents of young patients as well as physicians treating children with this ultra-rare condition.

ASH 2010 Report: A new era in first line CML treatment coming up?
